HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Jingze Biopharmaceutical (Hefei) / Equity Capital Markets

Jingze Biopharmaceutical (Hefei) (JBP HK)

<ul>
<li>JZB33 is expected to have more growth potential than JZB30. However, the rhFSH market is highly competitive. JZB30/JZB33 not only need to compete with MNCs but also domestic Big Pharma.</li>
<li>The "inverted pyramid" pipeline distribution leads to a high dependence JZB30, JZB33, JZB05 for Jingze's performance growth in the next 3-5 years, thus lacking sustained innovation and growth momentum.</li>
<li>Post-Money valuation was RMB3.09 billion after Series C+ Financing. We think valuation of Jingze should be lower than Henlius, <a href="https://www.smartkarma.com/entities/chengdu-kanghong-pharmaceutical-group-a" target="_blank" data-smartkarma-citation="entities:24723:1" rel="noopener">Chengdu Kanghong </a>due to the concerns on commercialization outlook/Biosimilar VBP.</li>
</ul>


JZB33 is expected to have more growth potential than JZB30. However, the rhFSH market is highly competitive. JZB30/JZB33 not only need to compete with MNCs but also domestic Big Pharma.
The "inverted pyramid" pipeline distribution leads to a high dependence JZB30, JZB33, JZB05 for Jingze's performance growth in the next 3-5 years, thus lacking sustained innovation and growth momentum.
Post-Money valuation was RMB3.09 billion after Series C+ Financing. We think valuation of Jingze should be lower than Henlius, Chengdu Kanghong due to the concerns on commercialization outlook/Biosimilar VBP.


Pre-IPO Jingze Biopharmaceutical (Hefei) - The Concerns and the Outlook

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front,  a number of companies are lining up to start 2H listing season, which is likely to be one of the busiest over the past few years.</li>
<li>On the placements front as well, given ongoing earnings annoucement there were only one large placement last week.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front,  a number of companies are lining up to start 2H listing season, which is likely to be one of the busiest over the past few years.
On the placements front as well, given ongoing earnings annoucement there were only one large placement last week.


ECM Weekly (18 August 2025)- Eve Energy, CNGR, Will Semi, 52 Toys, JSW, Bluestone, Tuas, Hexaware

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

<ul>
<li>Jingze Biopharm, a China-based clinical-stage biopharmaceutical company, is looking to raise at least USD 100 million via a Hong Kong listing. CICC and Guoyuan International are the joint sponsors.</li>
<li>In this note, we look at the company’s product pipeline, its pre-IPO investors, and management.</li>
<li>Our initial view is that the company’s core products, which are made of two biosimilars, are too thin for a listing, given the level of competition in respective market segments. </li>
</ul>


Jingze Biopharm, a China-based clinical-stage biopharmaceutical company, is looking to raise at least USD 100 million via a Hong Kong listing. CICC and Guoyuan International are the joint sponsors.
In this note, we look at the company’s product pipeline, its pre-IPO investors, and management.
Our initial view is that the company’s core products, which are made of two biosimilars, are too thin for a listing, given the level of competition in respective market segments. 


Jingze Biopharm (景泽生物) Pre-IPO: A Thin Pipeline of Biosimilars

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jingze Biopharmaceutical (Hefei) (JBP HK)

Pre-IPO Jingze Biopharmaceutical (Hefei) - The Concerns and the Outlook

"Inverted pyramid" pipeline distribution lead to high dependence JZB30/JZB33/JZB05 for Jingze's performance growth, thus lacking sustained...

Xinyao (Criss) Wang

ECM Weekly (18 August 2025)- Eve Energy, CNGR, Will Semi, 52 Toys, JSW, Bluestone, Tuas, Hexaware

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Jingze Biopharm (景泽生物) Pre-IPO: A Thin Pipeline of Biosimilars

China's Jingze Biopharm seeks to raise $100 million through Hong Kong listing, but concerns arise over thin product pipeline and competition in...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Jingze Biopharmaceutical (Hefei) - The Concerns and the Outlook

"Inverted pyramid" pipeline distribution lead to high dependence JZB30/JZB33/JZB05 for Jingze's performance growth, thus lacking sustained...

Xinyao (Criss) Wang

ECM Weekly (18 August 2025)- Eve Energy, CNGR, Will Semi, 52 Toys, JSW, Bluestone, Tuas, Hexaware

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Jingze Biopharm (景泽生物) Pre-IPO: A Thin Pipeline of Biosimilars

​China's Jingze Biopharm seeks to raise $100 million through Hong Kong listing, but concerns arise over thin product pipeline and competition in...

Ke Yan, CFA, FRM

China's Jingze Biopharm seeks to raise $100 million through Hong Kong listing, but concerns arise over thin product pipeline and competition in...